SCHEMBL2554

SCHEMBL2554

O=C(O)c1cc(Br)ccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
GLA P06280 1/20 0.59
DGAT1 O75907 1/20 0.52
AKR1C2 P52895 2/20 0.50
AKR1C1 Q04828 2/20 0.50
AKR1C4 P17516 1/20 0.50
AKR1C3 P42330 1/20 0.50
MYC P01106 1/20 0.49
NR4A1 P22736 1/20 0.49
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47
GPR35 Q9HC97 1/20 0.47
CES2 O00748 2/20 0.47
GALR3 O60755 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30722862 1.00 KDM4E (0.59) KDM4EGLADGAT1AKR1C2AKR1C1
SCHEMBL875504 0.83 ALDH1A1 (0.53) KDM4EGLADGAT1AKR1C2AKR1C1
SCHEMBL156346 0.83 DGAT1 (0.68) KDM4EGLADGAT1MYCNR4A1
SCHEMBL3652414 0.81 AKR1C3 (0.54) KDM4EGLAAKR1C2AKR1C1AKR1C3
SCHEMBL10082 0.81 DGAT1 (0.50) KDM4EGLADGAT1MYCNR4A1
Hydrochloric Acid SCHEMBL2349044 0.81 DGAT1 (0.66) KDM4EGLADGAT1MYCNR4A1
SCHEMBL181200 0.81 ALDH1A1 (0.52) KDM4EGLADGAT1AKR1C2AKR1C1
SCHEMBL29401981 0.81 ALDH1A1 (0.52) KDM4EGLADGAT1AKR1C2AKR1C1
SCHEMBL30374539 0.81 DGAT1 (0.50) KDM4EGLADGAT1MYCNR4A1
SCHEMBL351693 0.81 DGAT1 (0.71) KDM4EGLADGAT1CES2GALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111732594-B Preparation method of fluxaparide 苏州富士莱医药股份有限公司 2022-03-04 CN claimed
WO-2022036940-A1 PREPARATION METHOD FOR FLUZOPARIB 苏州富士莱医药股份有限公司 2022-02-24 WO claimed
CN-110229537-B Flame-retardant plastic-wood composite material with excellent water boiling resistance and preparation method thereof 黄山美森新材料科技股份有限公司 2021-05-11 CN claimed
CN-111732594-A Preparation method of fluxaparide 苏州富士莱医药股份有限公司 2020-10-02 CN claimed
CN-1244531-C Process for producing 5-bromo-2-fluorobenzoic boric acid AMERICAN CYANAMID CO (US) 2006-03-08 CN claimed
CN-1403430-A Process for producing 5-bromo-2-fluorobenzoic boric acid AMERICAN CYANAMID CO (US) 2003-03-19 CN claimed
CN-1087743-C Method for preparing 5-bromo-2-fluorobenzeneboronic acid AMERICAN CYANAMID CO (US) 2002-07-17 CN claimed
CN-1168887-A Method for preparing 5-bromo-2-fluorobenzeneboronic acid AMERICAN CYANAMID CO (US) 1997-12-31 CN claimed
EP-4725946-A1 IRAK4 DEGRADATION AGENT AND USE THEREOF Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) 2026-04-15 EP disclosed
EP-3921310-B1 NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS MEDIBIOFARMA S L (ES) 2026-01-14 EP disclosed
US-12509423-B2 Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug ALCHEMEDICINE, INC. (JP) 2025-12-30 US disclosed
EP-4660182-A1 NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2025-12-10 EP disclosed
US-20250368634-A1 PHENYL AMIDE COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. (US) 2025-12-04 US disclosed
WO-2025243042-A1 COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D THE UNIVERSITY OF LIVERPOOL (GB) 2025-11-27 WO disclosed
CN-1168887-A Method for preparing 5-bromo-2-fluorobenzeneboronic acid AMERICAN CYANAMID CO (US) 1997-12-31 CN disclosed
EP-0789688-A4 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1997-11-19 EP disclosed
EP-0789688-A1 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-08-20 EP disclosed
WO-1997009308-A1 INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-03-13 WO disclosed
EP-0295833-A1 Aromatic-Spiropiperidine oxazepinones (and thiones) A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1988-12-21 EP disclosed
US-4746655-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1988-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509423-B2 Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug ALDH2, ALDH1A1, ADH1A KDM4E 3876/4885GLA 1137/4885DGAT1 352/4885
US-20250368634-A1 PHENYL AMIDE COMPOUNDS AND METHODS OF USE AADAC, DBI, ASNS KDM4E 1995/4885GLA 2518/4885DGAT1 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.